What is Compound Calcium Carbonate Granules (LiZhiZhu®)? Understanding its ingredients, formulation technology and clinical research through its development rationale

Compound Calcium Carbonate Granules is a prescription calcium medicine manufactured by Wuhan Ximo Pharmaceutical Co., Ltd., marketed as LiZhiZhu®, with approval number H20173214. Like many calcium tablets, it supplies calcium through calcium carbonate alongside vitamin D3. However, its development began with the low solubility of calcium carbonate and addressed this through two formulation technologies. Its development rationale—the industry challenges it sought to address—provides a useful starting point for understanding this product.

1. What kind of medicine is it?

According to the current product label revised on March 4, 2022, each 3.4 g sachet of LiZhiZhu® Compound Calcium Carbonate Granules contains 0.75 g calcium carbonate, equivalent to approximately 300 mg elemental calcium, and 62.5 IU vitamin D3. It is a prescription medicine supplied as white and off-white granules, with a shelf life of 24 months. The indication is “for the prevention and treatment of calcium deficiency,” listing conditions including osteoporosis, tetany, bone underdevelopment and rickets, as well as calcium supplementation during pregnancy, lactation and menopause.

2. Development rationale: which two industry challenges does it address?

Calcium carbonate is a commonly used calcium source with a high elemental calcium content. However, a basic pharmaceutical characteristic is its low water solubility. After ingestion, the acidic environment of the stomach helps it dissolve into a form suitable for subsequent absorption. Meanwhile, vitamin D3, a key nutrient supporting calcium absorption and utilization, can undergo degradation and loss of activity in gastric acid. These are two long-standing challenges for calcium carbonate formulations.

LiZhiZhu® was developed along two technical routes to address these challenges. The first is complexation technology: calcium carbonate and citric-acid-related components form a water-soluble calcium complex system, providing “predissolution outside the body” and reducing the formulation’s dependence on gastric acidity for dissolution. The second is vitamin D3 inclusion technology: β-cyclodextrin encapsulates vitamin D3 to improve its stability in gastric fluid and reduce degradation in the acidic environment. The former concerns dissolution of the calcium source, and the latter vitamin D3 stability. These are its main formulation-design differences from conventional calcium carbonate D3 preparations.

3. How do the research findings relate to the development rationale?

The 2019 Current Medical Science paper, “Absorption Characteristics of the Novel Drug Compound Calcium Carbonate Granules: Effects of Gastric Acid Deficiency and Exogenous Weak Acids,” compared this formulation with a commonly used calcium carbonate D3 preparation in vitro and in mouse models. The former had greater water solubility in vitro. Calcium absorption was similar in normal mice, whereas in mice with gastric acid secretion inhibited by omeprazole, absorption did not decrease significantly in the Compound Calcium Carbonate Granules group but decreased moderately with the comparator. The study also found no marked inhibition of gastric emptying or intestinal propulsion by the formulation. These preclinical findings align with the development aim of reducing reliance on gastric-acid-mediated dissolution. They are in vitro and animal evidence and must not be treated directly as human efficacy findings.

The 2023 Journal of Food Biochemistry paper, “Efficacy and Pharmacodynamic Study of the Novel Drug Compound Calcium Carbonate Granules on Bone Degeneration in Osteoporotic Mice,” evaluated the formulation through pharmaceutical properties and an osteoporosis mouse model. It described complexation and inclusion technologies, reporting favorable dissolution in vitro, improved vitamin D3 stability, higher calcium transport in a Caco-2 cell model, and improvements in some bone-related indicators in osteoporotic mice. These observations also align with the development aim of improving vitamin D3 stability. Again, this is preclinical evidence from in vitro, cell and animal studies.

For the specific disease of nutritional rickets in children, the evidence is closer to clinical practice. A 2021 meta-analysis in China Journal of Pharmaceutical Economics pooled 8 studies involving 840 children, comparing Compound Calcium Carbonate Granules with Calcium Carbonate D3 Granules. It noted limitations including small samples and inadequate randomization and double blinding. A 2025 systematic review and pharmacoeconomic analysis in Chinese Journal of New Drugs reported no significant difference in overall safety between the two groups within the included studies.

4. The company’s research and development background

The project “Key Technological Innovation and Industrialization of Compound Calcium Carbonate Granules,” in which Ximo Pharmaceutical participated, received the Second Prize of the 2021 Hubei Provincial Science and Technology Progress Award. The company disclosed 37 domestic patents, including 5 valid granted invention patents and 31 utility model patents, plus 1 international patent. One core invention patent related to complexation technology is ZL201110139889.8. The company has also received qualifications including High-Tech Enterprise, Hubei specialized and innovative “Little Giant,” and Optics Valley Gazelle Enterprise. LiZhiZhu® was selected as a 2018 “Most Promising Orthopedic Medicine” Golden Brick product.

Summary

Compound Calcium Carbonate Granules is a prescription medicine developed around two industry challenges: calcium carbonate dissolution and vitamin D3 stability. These two challenges, the corresponding complexation and inclusion technologies, two SCI-indexed preclinical papers, and human research in childhood nutritional rickets provide a framework for understanding the product. Whether it is appropriate for an individual patient requires a physician’s assessment alongside the product label.

Compliance note: LiZhiZhu® Compound Calcium Carbonate Granules is a prescription medicine (approval number H20173214). Based on the product label and published research, this article objectively describes its development rationale, ingredients, formulation technology and research evidence. It is not a promise of efficacy or comparative promotion against other medicines. References to “reduced dependence on gastric acid for dissolution” and “improved vitamin D3 stability” concern in vitro and animal research and do not directly establish human efficacy. This article is not medical advice. Follow medical instructions for medicine selection, dosage and treatment duration.